- Report
- April 2023
- 145 Pages
United States
From €3223EUR$3,450USD£2,727GBP
- Report
- October 2023
- 140 Pages
Global
From €3362EUR$3,599USD£2,844GBP
- Report
- March 2024
- 200 Pages
Global
From €3877EUR$4,150USD£3,280GBP
- Report
- October 2023
- 145 Pages
Global
From €2943EUR$3,150USD£2,490GBP
- Report
- February 2024
- 120 Pages
Global
From €4438EUR$4,750USD£3,754GBP
- Report
- April 2023
- 150 Pages
Global
From €4531EUR$4,850USD£3,833GBP
- Report
- January 2024
- 142 Pages
Global
From €3970EUR$4,250USD£3,359GBP
- Report
- October 2021
- 202 Pages
Global
From €4157EUR$4,450USD£3,517GBP
- Report
- June 2022
- 209 Pages
Global
From €3363EUR$3,600USD£2,845GBP
- Report
- March 2024
- 89 Pages
Global
From €3500EUR$4,013USD£3,065GBP
- Report
- November 2023
- 250 Pages
Global
From €3335EUR$3,570USD£2,821GBP
The Subcutaneous Immunoglobulin (SCIg) market is a segment of the Immune Disorders Drugs market. SCIg is a form of immunoglobulin therapy used to treat a variety of immune-mediated diseases, such as primary immunodeficiencies, autoimmune diseases, and chronic inflammatory diseases. SCIg is administered through subcutaneous injections, which are less painful and more convenient than intravenous infusions. SCIg is also more cost-effective than intravenous immunoglobulin (IVIg).
SCIg is a rapidly growing market, driven by the increasing prevalence of immune-mediated diseases and the growing demand for more convenient and cost-effective treatments. The market is expected to continue to grow in the coming years, as more patients are diagnosed with immune-mediated diseases and as new treatments become available.
Some of the major players in the SCIg market include CSL Behring, Grifols, Kedrion, Octapharma, and Shire. Show Less Read more
